AutogenAI
PrivateLast Round
Series B
Dec 6, 2023
Est. Valuation
$92.86M
Total Funding Raised
$65.3M
Company Overview
AutogenAI operates in AI, Data & Cloud Infrastructure and is based in New York City, New York. Its latest recorded funding round was a Series B round in December 2023.
AutogenAI is a technology company that provides an AI-driven platform for creating and enhancing bidding proposals, streamlining the drafting process while ensuring high-quality content and consistency in messaging.
Sector
AI, Data & Cloud Infrastructure
Verticals
NLP & Conversational AI, Document Management, Workflow Automation
Business Model
B2B
Customer Profile
Subscription SaaS, Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
AutogenAI Comparables
Compare AutogenAI with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| GovDash | 88% | |
| Rohirrim | 85% | |
| Procurement Sciences AI | 83% |
For institutional investors. Book with your work email.
AutogenAI Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Dec 6, 2023 | ||||
| Series A | Jul 27, 2023 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
AutogenAI Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Blossom Capital | Series B, Series A |
| Salesforce Ventures | Series B |
| Spark Capital | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 1, 2026
Retained three G2 category awards for Best ROI, Fastest Implementation, and Best Support.
- Jan 1, 2026
Received authorization for its US-specific platform.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- expands_offices_toSep 24, 2026
AutogenAI Ltd has expanded its operations into Australia following a $39.5 million Series B funding round co-led by Salesforce Ventures and Spark Capital.
- expands_offices_toSep 24, 2026
Following a $39.5m Series B funding round co-led by Salesforce Ventures and Spark Capital, AutogenAI Ltd expanded its operations into the United States and Australia and grew its team into the hundreds, as reported on Sep 24th '26.
- has_revenueAug 10, 2026
In Sep '25, AutogenAI Ltd reaches $36.1M in revenue.
For institutional investors. Book with your work email.
AutogenAI Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about AutogenAI's valuation, stock price, and market status.
Is AutogenAI a public or private company?
AutogenAI is a private company.
What is the current stock price of AutogenAI?
AutogenAI is a private company, so its shares have no public market price. Caplight tracks AutogenAI's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is AutogenAI worth (valuation)?
AutogenAI's valuation is estimated at $92.9M based on funding round data.
Can I buy AutogenAI stock?
AutogenAI shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was AutogenAI's last funding round?
AutogenAI's most recent funding round was Series B on December 6, 2023.
Who are the main investors in AutogenAI?
Key investors in AutogenAI include Blossom Capital, Salesforce Ventures, Spark Capital.
Will AutogenAI IPO soon?
No public IPO plans have been announced for AutogenAI.
How can I track AutogenAI secondary market activity?
Caplight tracks bids, offers, and trades in AutogenAI's shares on secondary markets.